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function	 (LVDD,	n	=	5),	 possibly	 an	early	 stage	of	HF	with	preserved	EF	 (HFpEF).	
In	conclusion,	IgG	deposits	and	infiltrates	of	immune	cells	are	present	in	end‐stage	
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1  | INTRODUC TION














ation	with	 increased	 filling	pressures.7,8	One	of	 the	main	players	 in	
adverse	cardiac	remodelling	is	the	inflammatory	response.8‐11	In	the	
acute	 phase	 upon	 a	 myocardial	 infarction,	 mainly	 neutrophils	 and	
monocytes	are	important	for	the	clearance	of	necrotic	cells	and	de‐
bris.10	The	chronic	phase	of	remodelling	is	hallmarked	by	a	prolonged	








improved	 cardiac	 performance.14‐18	 Conversely,	 general	 inhibition	
of	the	immune	response	by	corticosteroids	or	intravenous	immuno‐
globulin	 (IVIG)	 administration	 showed	no	effect	on	mortality	 in	HF	
patients	compared	with	conventional	treatment.19‐23	These	previous	
observations	suggest	a	pathogenic	role	of	a	specific	antibody‐medi‐
ated	 immune	response.	 In	 line	with	this	hypothesis,	deposits	of	an‐


















2  | MATERIAL AND METHODS
2.1 | Patient population with end‐stage heart failure
Patient's	 myocardial	 tissue	 was	 stored	 in	 the	 cardiac	 tissue	 biobank	















2.2 | Patient population with early left ventricular 
diastolic dysfunction
Plasma	of	260	patients	with	different	stages	of	diastolic	dysfunction	
was	 collected	 in	 the	HELPFul	 study.	HELPFul	 is	 an	 ongoing	 single	
HFrEF.	In	addition,	both	LVDD	patients	and	end‐stage	HFrEF	patients	show	elevated	
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from	 zero	 to	 six	 points	 based	 on	minor	 or	major	 abnormalities	 of	
echocardiographic	 diastolic	 function	 parameters	 (ie	 septal	 and	 lat‐

















regions	with	 little	 fibrosis	 and	 the	absence	of	necrotic	 tissue.	The	
epicardial	 layer	 and	 any	 adipose	 tissue,	 if	 present,	 were	 removed	
from	 the	 tissue	 in	 further	 analyses.	 Both	 paraffin‐embedded	 and	
cryosections	were	obtained	from	the	myocardium.
2.4 | Immunohistochemistry (IHC) for the 
detection of inflammatory cells
Tissue	 sections	 (4	 μm)	 of	 formalin‐fixed	 and	 paraffin‐embedded	
(FFPE)	 myocardium	 were	 stained	 with	 H&E	 and	 consecutive	 sec‐
tions	 with	 markers	 for	 different	 immune	 cell	 types	 using	 immu‐
nohistochemistry.	 Sections	 were	 stained	 for	 T	 cells	 (CD3	 DAKO,	




performed	 using	 diaminobenzidine	 (DAB).	 Histological	 sections	
were	analysed	using	semi‐quantitative	analysis.	Immune	cell	infiltra‐













(IF) for the detection of immunoglobulins
Cryosections	 (8	μm)	of	human	myocardium	were	 incubated	with	
FITC‐labelled	 anti‐IgG1	 (Sigma,	 F0767,	 1:30),	 FITC‐labelled	 anti‐
IgG3	 (Sigma,	 F4641,	 1:15)	 and	 FITC‐labelled	 anti‐complement	
component	 3	 (C3c)	 (DAKO,	 F0201,	 1:10).	 Sections	 of	 diseased	
kidney	tissue	 (8	μm)	served	as	positive	control.	Negative	control	
stainings	were	included	in	which	an	antibody	without	fluorescent	
label	 was	 used.	 Slides	 were	 incubated	 with	 Sudan	 black	 (0.1%,	
Sigma‐Aldrich,	4197‐25‐5)	for	20	minutes	to	limit	background	lipo‐
fuscin	 fluorescence.	 To	 visualize	 the	 localization	 of	 the	 antibod‐
ies	 in	the	myocardium,	 images	were	taken	using	a	Zeiss	Axiovert	
200M	microscope.









ing	 the	 lysates	 for	2	hours	 at	4°C.	The	 samples	were	 then	 centri‐
fuged	 for	20	minutes	 (15 682 g	at	4°C).	Next,	 the	supernatant	was	
collected,	aliquoted	and	stored	at	−80°C.
2.7 | Multiplex immunoassay
Levels	 of	 IgM	 and	 IgG	 subclasses	 (IgG1,	 IgG2,	 IgG3,	 IgG4)	 were	
measured	in	tissue	lysates	and	fresh	plasma	samples	using	a	Bio‐Plex	
Pro™	Human	Isotyping	immunoassay	6‐plex	(Bio‐Rad,	171A3100M)	
according	 to	manufacturer's	 instructions.	Plasma	and	 tissue	 lysate	
immunoglobulin	levels	were	calculated	using	internal	standards.
2.8 | IgG immunoprecipitation, gel 
electrophoresis and Western blot
Immunoprecipitation	(IP)	of	IgG	was	performed	according	to	manu‐
facturer's	 protocol	 (Bio‐Rad).	 In	 brief,	 protein	 G‐coated	 magnetic	
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beads	(SureBeads™	Protein	G	Magnetic	Beads;	Bio‐Rad,	161‐4023)	
were	 washed	with	 PBS‐T	 (PBS	 pH	 7.4	 and	 0.1%	 Tween	 20;	 EMD	
Millipore,	9005‐64‐5)	and	 incubated	with	1	μg	of	goat	anti‐human	
IgG	 antibody	 (EMD	Millipore,	 AP112,	 1:400)	 for	 1	 hour.	 IgG‐cou‐
pled	 beads	 were	 incubated	 o/n	 with	 15	 μg	 protein	 from	 tissue	
lysates	diluted	in	PBS.	Magnetic	beads	were	washed	with	PBS	and	
dissolved	 in	40	μL	Laemmli	Buffer	and	1%	Nu‐Page	sample	reduc‐
ing	 agent	 (Invitrogen,	 NP0004)	 and	 incubated	 for	 10	 minutes	 at	
70°C.	The	precipitate	was	collected	and	used	for	gel	electrophore‐
sis	 and	Western	 blotting	 (WB).	 Total	 of	 15	μg	 protein	 per	 sample	
was	 loaded	on	 pre‐casted	Bolt	 4%‐12%	Tris‐Plus	Gels	 (Invitrogen,	
NW04120BOX)	 for	1	hour	at	160	V	 in	MOPS	SDS	running	buffer	
(Invitrogen,	NP0001‐02).	Proteins	were	transferred	to	PVDF	mem‐
branes	 (Millipore,	 IPVH00010)	 and	 incubated	 o/n	 with	 a	 primary	
antibody	(mouse	anti‐human	IgG;	Novus,	IG226,	1:400)	and	1	hour	
with	 a	 secondary	 HRPO	 polyclonal	 Rabbit	 antimouse	 IgG	 (Dako,	
P0260,	 1:2000).	 For	 visualization,	 a	 chemiluminescent	 peroxidase	





five	matched	 end‐stage	DCM	patients,	were	 collected.	 Peripheral	





(542040,	Greiner	 Bio‐One).	 The	 single	 cell	 suspension	was	 added	
to	an	antibody	mixture	containing	different	cell	surface	markers	to	
identify	B‐cell	 subtypes	 as	 described	 before.32	Cells	were	 stained	
with	 a	 fixable	 viability	 dye	 (eBioscience,	 eFluor‐506,	 65‐0866‐14).	
Viable	CD19+CD3−	B	lymphocytes	were	selected	for	further	gating	
of	 C24−CD38+	 plasmablasts	 and	 CD27−,	 IgG+,	 CD24+,	 and	 CD38+ 
transitional/regulatory	 B	 cells	 using	 gating	 strategy	 as	 described	
by	Meeuwsen	et	al.32	All	appropriate	controls	were	included	in	the	
experiments,	 including	isotype/subclass‐matched	primary	antibody	
of	 irrelevant	 specificity.	After	 flow	cytometry,	data	were	analysed	
using	Kaluza	1.5a	software	(Beckman	Coulter).
2.10 | Statistical analysis











3.1 | High levels of IgG deposits in the myocardium 



















     |  5van den HOOGen et al.
and	 DCM	 patients	 (Figure	 1A).	 On	 average,	 myocardial	 IHD	 IgG	
levels	were	2.7‐fold	higher	compared	to	DCM	(P	=	.01)	and	1.9‐fold	
higher	compared	to	controls	(not	significant;	Figure	1B).




ment	 factor	 C3c,	 myocardial	 sections	 were	 fluorescently	 stained	
for	IgG1,	IgG3	and	C3c	(Figure	2).	IgG1	showed	no	clear	staining	in	
both	 control	 and	 IHD/DCM	patients.	 IgG3	was	 visible	 in	 IHD	and	











to	acute	MI,	more	 infiltrating	 immune	cells	were	observed	 in	both	
the	 myocardium	 of	 DCM	 and	 IHD	 patients	 as	 compared	 to	 con‐
trols	 (Figure	3A).	 Semi‐quantitative	 analysis	 (Figure	3B‐D)	 showed	
a	significantly	higher	number	of	CD3+	T	cells,	CD68+	macrophages	
and	CD20+	B	cells	in	both	IHD	and	DCM	patients,	as	compared	to	
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3.4 | Increased IgG1 and IgG3 levels and decreased 
circulating regulatory B cells in HF patients
Flow	cytometry	was	performed	on	PBMCs	derived	from	10	end‐
stage	HFrEF	patients	(5	DCM	and	5	IHD)	and	stained	for	different	
B‐cell	markers	 to	 identify	 B‐cell	 subsets32	 (Figure	 4A).	 Data	 are	
presented	 as	 the	 percentage	 of	 total	 B‐cell	 count.	 The	 percent‐
age	of	plasmablasts	 (CD24‐CD38+)	 in	HF	patients	did	not	differ	











3.5 | Circulating pro‐inflammatory markers mostly 




regulatory	B	cells	 (CD38+CD24+;	P	=	 .04)	as	compared	 to	healthy	
controls	(Figure	5A,B).	In	addition,	IgG1	and	IgG3	levels	were	signifi‐
cantly	increased	in	IHD	patients	(IgG1	=	1.1	×	107	vs	4.5	×	106	ng/






3.6 | IgG1 and IgG3 levels as possible early 
markers of diastolic dysfunction in men
To	assess	whether	 IgGs	are	possible	markers	for	pre‐stage	HF,	we	
measured	 IgG1	 and	 IgG3	 levels	 in	 a	 cohort	 of	 patients,	 ranging	
from	only	 slightly	 elevated	 filling	 pressures	 to	more	 severe	 LVDD	
(Figure	 6).	Another	 advantage	of	 this	 unique	 cohort	 is	 that	 it	was	
specifically	designed	to	assess	sex	differences	in	the	progression	of	
LVDD	 to	HFpEF.	 Interestingly,	men	with	 LVDD	 show	 significantly	
increased	levels	of	IgG1	(8.2	×	106	vs	5.2	×	106	ng/mL,	P	=	.05)	and	
















plays	 an	 important	 role	 in	 adverse	 cardiac	 remodelling	 in	 HF.28 
Furthermore,	 deposits	 of	 IgG	 can	 be	 found	 in	 end‐stage	 HFrEF	
myocardium,27,33,34	 thereby	 suggesting	 the	 potential	 role	 of	 an	
(auto)‐immune	response.	However,	the	role	of	an	antibody‐medi‐











aemia‐reperfusion	 injury.	 In	 this	way,	 the	 immune	system	possibly	
becomes	 sensitized	 for	 these	 cardiac‐specific	 antigens.	 In	 DCM,	
the	myocardial	 damage	 is	 less	massive	 and	 therefore	 the	 immune	
system	 might	 be	 exposed	 to	 less	 cardiac‐specific	 epitopes	 possi‐
bly	resulting	in	a	 less	severe	antibody‐mediated	immune	response.	
Binding	of	 immunoglobulins	to	cardiac‐specific	antigens	on	cardio‐
myocytes	 can	 initiate	 the	 process	 of	 complement	 activation	 and	
antibody‐dependent	 cellular	 cytotoxicity	 (ADCC),	 resulting	 in	 lysis	
of	cardiomyocytes.29,35‐37	 In	DCM,	 it	has	also	been	described	 that	
immunoglobulins	 can	 directly	 bind	 to	 antigens	 expressed	 by	 the	




icity	 (CDC).	Using	 immunofluorescence,	we	observed	an	 increased	
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We	 also	 observed	 increased	 numbers	 of	macrophages,	 T	 cells	
and	B	cells	in	the	myocardium	of	HF	patients	compared	with	control	







Despite	 low	numbers	of	plasma	cells	 in	 the	myocardium	of	HF	
patients,	we	did	 find	an	 increase	 in	 the	number	of	plasmablasts	 in	
the	circulation,	albeit	this	fell	short	of	being	significant.	Plasmablasts	
develop	 upon	 antigen‐stimulation	 and	 secrete	 immunoglobulins.44 
The	 percentage	 of	 transitional/	 regulatory	 B	 cells	 was	 decreased	
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in	IHD	patients	compared	with	healthy	controls.	This	population	is	
characterized	by	its	immunosuppressive	capacity,	often	mediated	by	
IL‐10.45	A	potential	 increase	 in	 the	numbers	of	plasmablasts	and	a	
parallel/concomitant	 decrease	 in	 the	 numbers	 of	 immunosuppres‐
sive	transitional/regulatory	B	cells,	as	observed	in	our	IHD	patients,	
might	promote	the	putative	autoimmune	response	in	HF.
Consistent	 with	 our	 observations	 in	 the	 myocardium,	 we	 ob‐
served	 increased	 levels	of	 IgG1	and	 IgG3	 in	 fresh	plasma	 samples	








We	 demonstrated	 a	 significant	 correlation	 between	 the	 severity	
of	 LVDD	 and	 circulating	 levels	 of	 IgG1	 and	 IgG3	 in	men.	 Possibly	
already	 in	 this	 early	 stage,	 small	myocardial	 damage	 has	 occurred	
that	sensitizes	the	immune	system,	for	example	due	to	microvascu‐
lar	dysfunction	or	increased	wall	pressure.	In	patients	with	indeter‐













hearts	 and	 the	 low	 number	 of	 plasma	 samples	 used	 for	 the	 end‐
stage	HFrEF	patients.	Generally,	the	number	of	HTx	is	very	limited	
because	of	the	lack	of	donor	hearts.	In	case	a	donor	heart	is	not	used	
for	 transplantation,	and	a	consent	 is	available	 to	donate	 the	heart	





















In	 conclusion,	 our	 study	 demonstrates	 an	 increased	 inflamma‐
tory	 status	 in	 end‐stage	HFrEF,	mostly	pronounced	 in	 IHD,	which	
includes	 increased	amounts	of	 IgG	deposits,	 increased	numbers	of	
macrophages	 and	 lymphocytes	 in	 the	 myocardium,	 fewer	 transi‐
tional/regulatory	B	cells	and	increased	levels	of	circulating	IgG1	and	
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